Impact of Recipient Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
Open Access
- 31 October 2010
- journal article
- research article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 16 (10), 1463-1466
- https://doi.org/10.1016/j.bbmt.2010.05.006
Abstract
No abstract availableKeywords
Funding Information
- (The Dana Foundation), the American Italian Cancer Foundation, and the Gabrielle's Angel Foundation (P01-CA18029, CA78902, CA15704, HL36444 and TE 4540)
This publication has 19 references indexed in Scilit:
- Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activityBlood, 2007
- Atorvastatin Inhibits T Cell Activation through 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase without Decreasing Cholesterol SynthesisThe Journal of Immunology, 2007
- Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevanceClinical Pharmacology & Therapeutics, 2006
- Statin therapy and autoimmune disease: from protein prenylation to immunomodulationNature Reviews Immunology, 2006
- Statins induce calcium-dependent mitochondrial permeability transitionToxicology, 2006
- Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with TacrolimusAmerican Journal of Transplantation, 2005
- Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myelomaBone Marrow Transplantation, 2005
- Statin-induced immunomodulatory effects on human T cells in vivoAtherosclerosis, 2004
- Pharmacological interactions of statinsAtherosclerosis Supplements, 2002
- Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimusAtherosclerosis, 2001